717 related articles for article (PubMed ID: 26497339)
21. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
22. Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy.
Pham H; Sharma P
Can J Urol; 2018 Apr; 25(2):9228-9237. PubMed ID: 29679999
[TBL] [Abstract][Full Text] [Related]
23. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs.
La Torre A; Giupponi G; Duffy D; Conca A; Cai T; Scardigli A
Pharmacopsychiatry; 2016 Jan; 49(1):3-13. PubMed ID: 26569417
[TBL] [Abstract][Full Text] [Related]
24. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Schauer I; Madersbacher S
Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
[TBL] [Abstract][Full Text] [Related]
25. Management of Benign Prostatic Hyperplasia.
Kim EH; Larson JA; Andriole GL
Annu Rev Med; 2016; 67():137-51. PubMed ID: 26331999
[TBL] [Abstract][Full Text] [Related]
26. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
27. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis.
Favilla V; Russo GI; Privitera S; Castelli T; Giardina R; Calogero AE; Condorelli RA; La Vignera S; Cimino S; Morgia G
Aging Male; 2016 Sep; 19(3):175-181. PubMed ID: 27310433
[TBL] [Abstract][Full Text] [Related]
28. BPH/LUTS and ED: common pharmacological pathways for a common treatment.
Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R
J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757
[TBL] [Abstract][Full Text] [Related]
29. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
30. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
Xu Z; Jia RP
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
[TBL] [Abstract][Full Text] [Related]
31. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
32. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
[TBL] [Abstract][Full Text] [Related]
33. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
34. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.
Lee JY; Lee SH; Kim SJ; Kim CS; Lee HM; Kim CI; Chung BH
Urology; 2011 Jan; 77(1):171-6. PubMed ID: 20691464
[TBL] [Abstract][Full Text] [Related]
35. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
[TBL] [Abstract][Full Text] [Related]
36. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
Kamalov AA; Takhirzade AM
Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
[TBL] [Abstract][Full Text] [Related]
37. Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.
Marberger M
Adv Ther; 2013 Apr; 30(4):309-19. PubMed ID: 23584673
[TBL] [Abstract][Full Text] [Related]
38. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
Lepor H
Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
[TBL] [Abstract][Full Text] [Related]
39. [Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
Kamalov AA; Takhirzade AM
Urologiia; 2017 Dec; (6):160-163. PubMed ID: 29376615
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.
La Vignera S; Aversa A; Cannarella R; Condorelli RA; Duca Y; Russo GI; Calogero AE
Expert Opin Pharmacother; 2021 Feb; 22(2):179-189. PubMed ID: 32902360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
